Review

Experimental Outcomes of the Mediterranean Diet: Lessons Learned from the Predimed Randomized Controlled Trial

Dicle Kargin 1,2, Laura Tomaino 1,3 and Lluís Serra-Majem 1,4,5,*

1 Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain; dicle.kargin@marmara.edu.tr (D.K.);
laura.tomaino@unimi.it (L.T.)
2 Department of Nutrition and Dietetics, Institute of Health Sciences, Marmara University, 34854 Istanbul, Turkey
3 Department of Clinical and Community Health (DISCCO), Universita’ degli Studi di Milano, 20122 Milan, Italy
4 Complejo Hospitalario Universitario Insular-Materno Infantil (CHUIMI), Canarian Health Services, 35016 Las Palmas de Gran Canaria, Spain
5 Consorcio CIBER, M.P. Fisiopatologia de la Obesidad y Nutricion (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
* Correspondence: lluis.serra@ulpgc.es

Received: 14 October 2019; Accepted: 15 November 2019; Published: 6 December 2019

Abstract: The Mediterranean Diet (MD) is, culturally and historically, the nutritional pattern shared by people living in the olive-tree growing areas of the Mediterranean basin. It is of great importance for its potential preventive effect against cardiovascular diseases (CVDs). The PREvenció n con DIeta MEDiterránea (PREDIMED) study, a Spanish multicentre randomised controlled trial (RCT), was designed to assess the long-term effects of the MD, without any energy restriction, on the incidence of CVD in individuals at high cardiovascular (CV) risk. Since its inception, it gave a great contribution to the available literature on the issue. It is well known that, in the field of the health sciences, RCTs provide the best scientific evidence. Thus, the aim of the present review is to analyse the results of the RCTs performed within the frame of the PREDIMED study. Our findings showed that MD has beneficial effects in the primary prevention of CVDs, diabetes and in the management of metabolic syndrome.

Keywords: PREDIMED; Mediterranean diet; dietary intervention; randomized controlled trials; cardiovascular disease; type-2 diabetes mellitus; metabolic syndrome

1. Introduction

The Mediterranean diet (MD) is a nutritional model proposed by Ancel Keys, based on the dietary traditions shared around the fifties (1950s) by populations that inhabited the Hellenic peninsula, Italy, and the other countries overlooking the Mediterranean Sea [1]. In descriptive terms, MD is the dietary pattern historically and culturally prevailing among people residing in the olive tree-growing areas of the Mediterranean region before globalization made its effect on lifestyle, diet included [1,2]. Even if the different regions in these areas have their own dietary traditions, they could be considered as variants of the most comprehensive MD [3]. Graphically, it is represented by a pyramid that represents food according to their frequency of intake: rarely to often (weekly or daily), from the basis to the apex, respectively [4].

The MD model is closely related to the history of civilization of the areas surrounding the Mediterranean Sea, and the foods characterizing this dietary pattern have been part of the diet and
consumed since many centuries ago. In ancient times, the staple food of the populations residing in the setting of the Mediterranean Sea were non-starchy vegetables (present in abundance and assortment), minimally processed whole-grain cereals, legumes, nuts, and seeds [5]. Nowadays, the MD is composed by plentiful use of olive oil, high consumption of fruit, vegetables, legumes, cereals and nuts, regular but moderate intake of wine (especially red wine) with meals, moderate consumption of fish, seafood, fermented dairy products (yogurt and cheese), poultry and eggs; and limited consumption of red and processed meats and sweets [6].

However, the investigation of the MD’s effects on health did not begin until the 20th century. The first study to observe a protective effect of the MD or some of its components was the Seven Countries Study [7]. It reported a strong inverse association between monounsaturated fatty acid intake (the main source of fat from olive oil, essential component of the MD) and overall mortality, especially due to coronary heart disease (CHD) and cancer. Afterwards, MD and its effects on health were mostly investigated by means of observational studies and personal reviews, with the exception of the Lyon Heart Study in France, which revealed that modified MDs were associated with remarkable reductions in CHD event rates and cardiovascular (CV) mortality [8], and other small scale clinical trials [9]. In recent times, the number of randomized controlled trials (RCTs) and meta-analyses increased significantly, with the objective to examine the impact of the MD on various health outcomes [10].

The MD pattern reached considerable importance due to its role in the prevention of cardiovascular diseases (CVDs). The inverse association between adherence to MD and CVD mortality, reported by Seven Countries study [7], paved the way for the increasing importance that MD acquired in cardiovascular epidemiology [1,7]. As a result, the American Heart Association qualified the Mediterranean Food Pattern as potentially effective for the prevention of CHD, though emphasizing the need of more studies before suggesting people to pursue a MD pattern [11].

Although the first references to the benefits of MD on health focused on the protective effect against CVDs, its effects on other health issues were later investigated. For instance, the available literature reports the inverse association between specific nutrients, food components and the Mediterranean dietary pattern, and several health conditions, such as: Specific types of cancer, diabetes mellitus, obesity, cognitive decline and mental health, respiratory diseases, osteoarthritis, and quality of life or healthy aging [10].

To date, several studies have been conducted in Spain and other Mediterranean countries in the scope of MD and its relationship with health, and the evidence of the beneficial role of this pattern is being constantly enhanced [12]. The PREvención con DIeta MEDiterránea (PREDIMED) study is a primary prevention multicentre randomised controlled trial (RCT) designed to test the hypothesis that the MD would be superior to a low-fat diet for CVD protection in asymptomatic patients at high CV risk [13].

The PREDIMED Study

The PREDIMED study is a large, parallel group, multicentre, randomized, controlled, nutritional intervention trial designed to assess the effects of the Mediterranean Diet on the primary prevention of CVD (www.predimed.es) [14]. The study was conducted in Spain from 2003 to 2011 and was funded exclusively by Instituto de Salud Carlos III, while food industries provided Extra Virgin Olive Oil (EVOO) and nuts free of charge.

The protocol, design and methods of the trial have been reported previously [15,16] and their detailed description goes beyond our objectives. To sum up, community-dwelling men (aged 55–80 years old) and women (aged 60–80) without predetermined diagnosis of CVD were included in the study, and were considered acceptable to participate if they had either type 2 diabetes mellitus (DM) or ≥ 3 of the following major CV risk factors: hypertension, high plasma low-density lipoprotein (LDL) cholesterol, low plasma high-density lipoprotein (HDL) cholesterol, overweight or obesity (BMI ≥ 25 kg/m²), current history of smoking and family history of premature CHD. The enlistment period lasted from October 2003 to June 2009, and enrolled 7447 participants that were randomly assigned to one of
the three nutritional intervention groups (ratio 1:1:1) in the Spanish Primary Care Centres affiliated to 11 recruiting centres. Two groups were prescribed a MD enriched with either Extra Virgin Olive Oil (EVOO) (n = 2543) or nuts (walnuts, almonds and hazelnuts) (n = 2454), and the third group (control) was prescribed a low-fat diet (n = 2450). None of the three dietary protocols included in the trial provided energy restrictions, and no intervention on participants’ physical activity status was performed.

Validated food frequency questionnaires covering 137 food items plus vitamin/minerals supplements were collected yearly by trained dietitians, and adherence to the MD was assessed through a 14-items questionnaire [17]. Fasting blood and urine samples were obtained, and serum, plasma and DNA specimens were stored. Biomarkers of adherence to the supplemental foods (urinary hydroxytirosol as marker of EVOO consumption and plasma α-linolenic acid as marker of walnut consumption) were determined in random sub-samples [18].

In addition to the institutional review board of the Hospital Clinic in Barcelona, Spain (approved on 16 July 2002), the institutional review boards of each recruitment centre also approved the study protocol, and participants gave their written informed consent.

The primary aim of the trial was to assess the effects of two MDs (MD + EVOO or MD + nuts) on a composite endpoint of cardiovascular death, myocardial infarction and stroke (primary outcome), compared to a low-fat control diet. Secondary endpoints were: death of any cause, incidence of heart failure, DM, dementia or other neurodegenerative disorders, and major cancers (colorectal, breast, lung, stomach and prostate). To better assess the impact of dietary changes on the risk of clinical events, intermediate outcomes were also evaluated, for instance changes in blood pressure (BP), blood lipids levels, fasting glycaemia, weight gain, and markers of inflammation [16].

According to the pyramid of evidence relative to health science, randomized clinical trials (RCTs) provide the best, and most robust and accountable scientific evidence [19]. Thus, the aim of the present paper is to review and analyse the results of the main and secondary outcomes, as well as the post hoc analyses within the frame of the PREDIMED study.

2. Materials and Methods

The research was conducted in PubMed, and included studies published from February 2006 to August 2019. The MeSH term “PREDIMED” was used as a key word. Titles and abstracts were independently scanned to include all potential studies identified as a result of the researches. The exclusion criteria were: studies not carried out within the scope of PREDIMED, protocols, letters, commentaries, reviews, studies related to PREDIMED-Plus and studies written in languages other than English. We obtained information for the following variables: number of participants at baseline and at the end of the intervention, characteristics of the participants, duration of the intervention, main objective of the intervention, and conclusions, as they appeared in the article.

3. Results

The PubMed search resulted in 375 abstracts. After applying the exclusion criteria, 197 articles remained for analysis. Since the main purpose of our review was to examine only experimental studies, we excluded observational studies, including cross-sectional, case control and cohort studies, as shown in Figure 1.
Figure 1. Flow chart of the studies’ selection process.

The main characteristics of the 44 randomized controlled PREDIMED studies and their effects on CVDs and other health outcomes included in our review are shown in Tables 1–3.
Table 1. Characteristics of the RCTs conducted within the frame of the PREDIMED study, investigating the role of Mediterranean Diet (MD) on cardiovascular disease (CVD) and cardiovascular risk factors.

| Aim of the Study | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study | 1st Author, Journal, Year | Ref. |
|------------------|-------------------|--------------------------|---------------------------|-------------------------|------|
| **Cardiovascular Disease** | | | | | |
| Incidence of primary endpoint (a composite of CV events: Non-fatal acute myocardial infarction, non-fatal stroke or death from CV causes) | 7447 | 4.8 | MD + EVOO vs control: HR (95% CI) IITT adjusted analysis * = 0.69 (0.53-0.91) | Estruch et al. N. Engl. J. Med. 2018 | [15] |
| | | | MD + Nuts vs control: Primary endpoint excluding site D and second household members * = 0.72 (0.54-0.95) | | |
| | | | * The intention-to-treat analysis (ITT) included 7447 participants. | | |
| | | | The analysis included 6403 participants. Second members of the same household (n = 423) and participants from site D (n = 617) were excluded. | | |
| Incidence of heart failure | 7403 | 4.8 | MD + EVOO: HR (95% CI) * = 0.68 (0.44-1.13) p = 0.139 | Papadaki et al. Eur. J. Heart Fail. 2017 | [20] |
| | | | MD + Nuts: HR (95% CI) ** = 0.92 (0.56-1.49) p = 0.725 | | |
| | | | * Models stratified according to centre and history of diabetes and used robust variance estimators | | |
| | | | ** Models stratified according to centre and history of diabetes and used robust estimate of the variance adjusted for intra-cluster correlation, considering members of the same household and participants in the same clinics of centre D as clusters. | | |
| Incidence of atrial fibrillation | 6705 | 4.7 | MD + EVOO: HR (95% CI) = 0.62 (0.45-0.85) p = 0.003 | Martinez-González et al. Circulation 2014 | [22] |
| | | | MD + Nuts: HR (95% CI) = 0.89 (0.65-1.20) p = 0.43 | | |
| **Cardiovascular Risk Factors** | | | | | |
| Long-term consumption of a MD could decrease the atherogenicity of LDL particles | 210 | 1.0 | LDL lag time (compared to baseline): MD-EVOO: +6.7%, p < 0.001 | Hernaez et al. Mol. Nutr. Food Res. 2017 | [23] |
| | | | Cholesterol content in LDL (versus low-fat diet): MD-Nuts: +6.4%, p = 0.002 | | |
| | | | The cytotoxicity of LDL (compared to baseline): MD-EVOO: +2.41%, p = 0.013 | | |
| | | | MD-Nuts: −13.4%, p = 0.019 | | |
Effects of high polyphenol consumption on BP and its relation about production of plasma NO

Effect of 1-year follow-up on:

- Serum stable NO metabolites concentration
- Serum ET-1 concentrations

Changes in BP associated with changes in plasma NO (unadjusted model):

| Systolic BP, coef. B (95% CI) | MD + EVOO vs control | MD + Nuts vs control |
|-------------------------------|-----------------------|---------------------|
| -6.14 (~12.04 to -2.33) | p = 0.042 | -2.69 (~8.62 to -3.24) | p = 0.372 |
| -5.23 (~8.20 to -2.25) | p = 0.001 | -1.74 (~4.73 to 1.25) | p = 0.233 |

Table 2. Mean differences (95% CI) in the expression of circulating markers of plaque instability from baseline to 1-months:

| VCAM (ng/mL) | ICAM (ng/mL) | sICAM (ng/mL) | IL-6 (pg/mL) | CRP (mg/mL) |
|--------------|--------------|---------------|--------------|-------------|
| MD + EVOO    | MD + Nuts    | Low-fat diet   | p * |
| (~251 to -252) * | (~327 to -89.6) * | (~173 to 61.5) | 0.30 |
| (~220)               | (~303)              | (15.5 to 109) * | 0.04 |
| (~273 to -166) * | (~7.7 to -1.7) * | (~5.3 to 0.9) | 0.55 |
| (~4.5 to 1.2) | (~0.4) | 0.3 |
| (~0.9 to 0.3) * | (~1.0 to 0.2) * | (~1.1 to 1.7) * | 0.55 |
| (~1.2) | (~1.4) | (~0.3) |
| (~2.4 to -1.6) * | (~2.1 to -0.7) * | (~1.3 to 0.8) |

*significant difference (p < 0.05) between before and after the intervention.
Table 1. Cont.

| Aim of the Study | Number of Subjects | Follow-Up (Years) | Main Results of the Study | 1st Author, Journal, Year | Ref. |
|------------------|-------------------|------------------|---------------------------|---------------------------|------|
| **MD effect on 24-h ambulatory BP, blood glucose, and lipids** | 235 | 1.0 | Ambulatory BP, blood glucose and lipids changes at 1 year: | | |
|  |  |  | MD-EVOO | MD-Nuts | Control | p * |
| Systolic BP (24 h) | -2.3 | -2.6 | 1.7 | <0.001 |
| (mg/dL) | (-4.0 to −0.5) | (-4.3 to −0.9) | (-0.1 to 3.5) |
| Diastolic BP (24 h) | -1.2 | -1.2 | 0.7 | 0.017 |
| (mg/dL) | (-2.2 to −0.2) | (-2.2 to −0.02) | (-0.4 to 1.7) |
| Glucose (24 h) | -6.13 | -4.61 | 3.51 | 0.016 |
| (mg/dL) | (-11.62 to −0.64) ° | (-9.82 to 0.60) | (-0.51 to 7.54) |
| Total cholesterol (24 h) | -11.3 | -13.6 | -4.6 | 0.043 |
| (mg/dL) | (-16.8 to −5.7) | (-18.3 to −9.0) ° | (-9.9 to 0.6) |
| Triglycerides (24 h) | -10.3 | -6.7 | -4.7 | 0.774 |
| (mg/dL) | (-22.9 to 2.3) | (-15.7 to 2.3) | (-16.4 to 7.1) |
| LDL cholesterol (24 h) | -6.5 | -11.3 | -5.8 | 0.211 |
| (mg/dL) | (-11.5 to −1.6) | (-15.9 to −6.6) | (-10.5 to −1.2) |
| HDL cholesterol (24 h) | 0.48 | 0.36 | 0.40 | 0.986 |
| (mg/dL) | (-0.68 to 1.64) | (-0.53 to 1.25) | (-0.56 to 1.36) |
|  |  |  | * between group differences |  |  |
|  |  |  | ° significant differences compared to the control group (Bonferroni multiple comparisons) |  |  |

| **Effect of the MD on heart failure biomarkers** | 930 | 1.0 | Mean (95% CI), between-group difference |  |  |
|  |  |  | MD + VOO vs low-fat diet |  |  |
| NT-proBNP, pg/mL | -70.3(-133 to −7.37) | -84.7 (-145 to −24.5) | p = 0.029 | |  |
| p = 0.006 |  |  |  |  |  |
| Oxidized LDL, U/L | -8.27 (-13.9 to -2.6) | -4.20 (-9.82-14.2) | p = 0.04 | |  |
| p = 0.143 |  |  |  |  |  |
| Lipoprotein(a), mg/dL | -4.17 (-8.12 to 0.04) | -2.62 (-6.36-1.13) | p = 0.170 | |  |
| Urinary albumin, mg/l | 4.55 (-4.73 to 13.7) | 1.12 (-8.22 to 10.4) | p = 0.336 | |  |
| p = 0.812 |  |  |  |  |  |
| Urinary albumin/creatinine, mg/g | 6.25 (-9.3 to 21.8) | 3.54 (-12.1 to 19.1) | p = 0.428 | |  |
| * between group differences |  |  | ° significant differences compared to the control group (Bonferroni multiple comparisons) |  |  |

Doménech et al. Hypertension 2014 [27]
Nutrients 2019, 11, x; doi: FOR PEER REVIEW www.mdpi.com/journal/nutrients

Table 1. Cont.

| Aim of the Study                                         | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study                                                                 | 1st Author, Journal, Year | Ref.       |
|----------------------------------------------------------|--------------------|--------------------------|------------------------------------------------------------------------------------------|---------------------------|------------|
| Incidence of Peripheral Artery Disease (PAD)             | 7435               | 4.8                      | HR (95% CI) for PAD by intervention group: MD + EVOO HR (95% CI) 0.32 (0.19-0.56) MD + Nuts HR (95% CI) 0.51 (0.32-0.83) | Ruiz-Carela et al. JAMA 2014 | [29]       |
| Mean differences in BP changes after 4 years follow-up (median follow-up 3.8 years), unadjusted analysis: |                    |                          | MD + EVOO vs control group Systolic BP 0.42 (−0.46 to 1.30) p = 0.35 Diastolic BP −1.41 (−1.92 to −0.91) p < 0.001 | Toledo et al. BMC medicine 2013 | [30]       |
| Effects of MD on BP³                                       | 7158               | 3.8                      | MD + Nuts vs control group Systolic BP −0.90 (−1.77 to −0.03) p = 0.04 Diastolic BP −0.61 (−1.12 to −0.09) p = 0.02 |                          |            |
| Effects of MD on progression of subclinical carotid atherosclerosis | 187                | 1.0                      | MD + VOO vs low-fat diet 1-year change in IMT 0.016 (−0.043; 0.011) MD + Nuts vs low-fat diet 0.033 (−0.056; 0.088) Control group 0.010 (−0.026; 0.005) P 0.38 | Muñiz-Fernández et al. Atherosclerosis 2011 | [31]       |
| Baseline IMT ≥ 0.9 mm *                                    |                    |                          | P 0.04                                                                                     |                           |            |
| * 1-year change for age, sex ah hyperlipidemia at baseline among those with baseline IMT ≥ 0.9 mm. |                    |                          |                                                                                           |                           |            |
| The short-term effects of MD versus those of a low-fat diet on intermediate markers of CV risk. | 772                | 0.25                     | MD + VOO vs low-fat diet Mean (95% CI between-group difference *) 0.09 (−0.12 to 0.29) p = 0.40 MD + Nuts vs low-fat diet Mean (95% CI between-group difference *) 0.15 (−0.06 to 0.35) p = 0.165 | Estruch et al. Ann. Int. Med. 2006 | [32]       |
| BMI, kg/m²                                                |                    |                          | 0.09 (−0.12 to 0.29) p = 0.40                                                                 |                           |            |
| Systolic BP                                               |                    |                          | −5.9 (−8.7 to −3.1) p < 0.001                                                                 |                           |            |
| Diastolic BP                                              |                    |                          | −1.60 (−3.00 to −0.01) p = 0.048                                                              |                           |            |
| HOMA index ‡                                              |                    |                          | −0.91 (−1.40 to −0.46) p < 0.001                                                             |                           |            |
| Total cholesterol, mmol/L                                 |                    |                          | −0.09 (−0.25 to 0.07) p = 0.26                                                               |                           |            |
| LDL, mmol/L                                               |                    |                          | −0.10 (−0.25 to 0.04) p = 0.177                                                              |                           |            |
| HDL, mmol/L                                               |                    |                          | 0.08 (0.04 to 0.10) p < 0.001                                                                |                           |            |
| Triglycerides, mmol/L                                     |                    |                          | −0.08 (−0.20 to 0.04) p = 0.21                                                              |                           |            |
| Cholesterol-HDL, cholesterol ratio                        |                    |                          | −0.38 (−0.55 to −0.22) p < 0.001                                                            |                           |            |

BMI: Body Mass Index; BP: Blood Pressure (mmHg); CV: Cardiovascular; MD: Mediterranean Diet; ET-1: Endothelin 1; EVOO: Extra Virgin Olive Oil; HDL: High-Density Lipoprotein; HOMA: Homeostatic Model Assessment; ICAM: Soluble Intercellular Adhesion Molecule; IL-6: Interleukin 6; IMT: Intima-Media Thickness; LDL: Low-Density Lipoprotein; MCP-1: Monocyte Chemotactic Protein 1; NO: Nitric Oxide (Um); NT-proBNP: N-terminal pro-brain natriuretic peptide; Se-Sel: Soluble E Selectin; TNF- Α: Tumor Necrosis Factor Alpha; VCAM: Vascular Cell Adhesion Molecule; VOO: Virgin Olive Oil.

* Determined only for 305 participants without diabetes

** Adjusted for centre, age, sex and baseline body weight
Table 2. Characteristics of the RCTs conducted within the frame of the PREDIMED study, investigating the role of Mediterranean Diet (MD) on diabetes mellitus (DM), metabolic syndrome (MetS) and obesity.

| Aim of the Study | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study | 1st Author, Journal, Year | Ref. |
|------------------|--------------------|--------------------------|---------------------------|--------------------------|------|
| **Diabetes Mellitus** |                    |                          |                           |                          |      |
| Effects of MD versus a low-fat diet on the need for glucose-lowering medications | 3230 T2DM | 3.2 | HR (95% CI) of starting a 1st glucose-lowering medication *: MD + EVOO 0.78 (0.62–0.98), MD + Nuts 0.89 (0.71–1.12), Both MDs vs control *** 0.85 (0.69–1.05) | Basterra-Gortari et al. Diab. Care. 2019 | [33] |
| Probability of requiring insulin therapy, HR (95% CI) **: MD + EVOO 0.87 (0.66–1.11), MD + Nuts 0.89 (0.69–1.14), Both MDs vs control 0.92 (0.73–1.16) | | | | | |
| * multivariable analysis adjusting for baseline characteristics and propensity scores. ** adjusted HRs after a mean follow-up of 5.1 years. *** sensitivity analysis after excluding second members of the same household and all participants form site D | | | | | |
| Long-term effect of a MD on microvascular diabetes complications | 3614 T2DM | 6.0 | HR (95% CI) of starting a 1st glucose-lowering medication *: MD + EVOO 0.56 (0.32–0.97), MD + Nuts 0.63 (0.35–1.11), Both MDs vs control 0.60 (0.37–0.96) | Díaz-López et al. Diab. Care. 2015 | [34] |
| Probability of requiring insulin therapy, HR (95% CI): MD + EVOO 1.15 (0.79–1.67), MD + Nuts 1.06 (0.72–1.58), Both MDs vs control 1.11 (0.79–1.55) | | | | | |
| (Adjusted model) | | | Eratum: | | |
| | | | Diabetic retinopathy, HR (95% CI): MD + EVOO 0.57 (0.33–0.98), MD + Nuts 0.62 (0.34–1.11), Both MDs vs control 0.59 (0.37–0.95) | Díaz-López et al. Diab. Care. 2018 | [35] |
| (Adjusted model) | | | Diabetic nephropathy, HR (95% CI): MD + EVOO 1.22 (0.83–1.81), MD + Nuts 1.15 (0.76–1.73), Both MDs vs control 1.19 (0.84–1.69) | | |
| Incidence of diabetes | 3541 | 4.1 | HR (95% CI) of developing diabetes: MD + EVOO vs control 0.69 (0.51–0.92), MD + Nuts vs control 0.81 (0.61–1.08), Both MDs vs control 0.75 (0.58–0.96), Multivariate-adjusted 0.60 (0.43–0.85) | Salas-Salvadó et al. Ann Int Med. 014 | [36] |

* multivariable analysis adjusting for baseline characteristics and propensity scores. ** adjusted HRs after a mean follow-up of 5.1 years. *** sensitivity analysis after excluding second members of the same household and all participants form site D.
### Table 2. Cont.

| Aim of the Study                                                                 | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study                                                                 | 1st Author, Journal, Year | Ref. |
|---------------------------------------------------------------------------------|--------------------|--------------------------|------------------------------------------------------------------------------------------|---------------------------|------|
| **Metabolic Syndrome**                                                           |                    |                          | Plasmatic antioxidant capabilities in Metabolic Syndrome (MetS) patients                  |                           |      |
|                                                                                | 75                 | 5.0                      | Plasma and red blood cells antioxidant and pro-oxidant enzyme activities (mean ± SEM) at the end of the intervention: |                           |      |
|                                                                                |                    |                          | Enzyme                                                                                   |                           |      |
|                                                                                |                    |                          | Superoxide dismutase activity (pkat/L)                                                    |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 11.6 ± 1.3 *              |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 14.2 ± 1.4 *              |      |
|                                                                                |                    |                          | Low-fat diet                                                                              | 6.69 ± 1.43               |      |
|                                                                                |                    |                          | * Significant differences vs. the control group (p < 0.05)                                |                           |      |
|                                                                                |                    |                          | * p-value obtained by ANCOVA                                                              |                           |      |
|                                                                                |                    |                          | **Blood cells**                                                                           |                           |      |
|                                                                                |                    |                          | Superoxide dismutase activity (pkat/mL)                                                  |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 2.25 ± 0.17               |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 2.12 ± 0.13               |      |
|                                                                                |                    |                          | Low-fat diet                                                                              | 2.53 ± 0.18               |      |
|                                                                                |                    |                          | Xanthine oxidase activity (U/L)                                                            |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 39.7 ± 3.7 *              |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 33.6 ± 3.4 *              |      |
|                                                                                |                    |                          | Low-fat diet                                                                              | 22.3 ± 2.8                |      |
|                                                                                |                    |                          | * Significant differences vs. the control group (p < 0.05)                                |                           |      |
|                                                                                |                    |                          | * p-value obtained by ANCOVA                                                              |                           |      |
|                                                                                |                    |                          | Catalase activity (U/L)                                                                   |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 202 ± 10 *                |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 204 ± 10 *                |      |
|                                                                                |                    |                          | Low-fat diet                                                                              | 246 ± 10                  |      |
|                                                                                |                    |                          | Xanthine oxidase activity (U/mL)                                                          |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 71.3 ± 3.7               |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 61.4 ± 3.6               |      |
|                                                                                |                    |                          | Low-fat diet                                                                              | 64.8 ± 3.4               |      |
|                                                                                |                    |                          | * Significant differences vs. the control group (p < 0.05)                                |                           |      |
|                                                                                |                    |                          | * p-value obtained by ANCOVA                                                              |                           |      |
|                                                                                |                    |                          | **Incidence of diabetes during follow-up**                                               |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 1.10 (0.94–1.30)          |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 1.08 (0.92–1.27)          |      |
|                                                                                |                    |                          | (Multivariable adjusted model)                                                           |                           |      |
|                                                                                |                    |                          | Babio et al. [38]                                                                         |                           |      |
|                                                                                |                    |                          | **Reversion of MetS status**                                                              |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 1.35 (1.15–1.58)          |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 1.28 (1.08–1.51)          |      |
|                                                                                |                    |                          | (Multivariable adjusted model)                                                           |                           |      |
|                                                                                |                    |                          | Estruch et al. [39]                                                                        |                           |      |
|                                                                                |                    |                          | **MD effects on MetS status**                                                             |                           |      |
|                                                                                | 1224               | 1.0                      | Crude OR (95% CI) for MetS reversion:                                                      |                           |      |
|                                                                                |                    |                          | Crude OR (95% CI) for incident MetS among individuals without it at baseline:            |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 1.4 (0.9–2.1)             |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 1.7 (1.1–2.7)             |      |
|                                                                                |                    |                          | Salas-Salvadó et al. [39]                                                                  |                           |      |
|                                                                                |                    |                          | **Obesity**                                                                               |                           |      |
|                                                                                |                    |                          | Weight and waist circumference changes during the follow-up in the intervention groups compared with the control group. Coefficient B (95% CI), multivariable adjusted. |                           |      |
|                                                                                |                    |                          | MD + EVOO                                                                                 | 0.401 (–0.830 to 0.030) p = 0.056 |      |
|                                                                                |                    |                          | MD + Nuts                                                                                 | 0.016 (–0.453 to 0.421) p = 0.942 |      |
|                                                                                |                    |                          | Control                                                                                  | 0                         |      |
|                                                                                |                    |                          | Estruch et al. [40]                                                                        |                           |      |

---

**Note:** ANCOVA = Analysis of Covariance; CI = Confidence Interval; EVOO = Extra Virgin Olive Oil; FFM = Free Fat Mass; HR = Hazard Ratio; MD = Mediterranean Diet; MetS = Metabolic Syndrome; OR = Odds Ratio; Q = Quartile; TAC = Total Antioxidant Capacity; TFM = Total Fat Mass; TrFM = Truncal Fat Mass; WC = Waist Circumference; %TBF = percentage of Total Body Fat.
Table 2. Cont.

| Aim of the Study | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study | 1st Author, Journal, Year | Ref. |
|------------------|--------------------|--------------------------|---------------------------|---------------------------|------|
| Effect of MD on anthropometric variables and body composition parameters | 305 | 1.0 | % change in the anthropometric and body composition variables: | | |
| | | | MD + EVOO | MD + Nuts | Control | | |
| | | Weight, kg | -1.1 (-2.0 to -0.2) | -0.7 (1.7 to 0.3) | -1.2 (-2.2 to -0.3) | | |
| | | BMI, kg/m² | -1.1 (-2.0 to -0.2) | -0.8 (-2.3 to 0.8) | -1.1 (-2.2 to 0.2) | | |
| | | WC, cm | -0.9 (-2.0 to -0.2) | -2.2 (-3.3 to -1.0) | -2.9 (-4.1 to -1.6) | | |
| | | %TBW | -0.1 (-2.4 to 2.2) | 1.3 (-1.4 to 3.8) | 3.3 (1.0 to 5.7) | | |
| | | FFM | -1.0 (-2.4 to 0.3) | -0.8 (-2.4 to 0.8) | -2.8 (-4.0 to -1.6) | | |
| | | TrFM, kg | -0.6 (-4.1 to 2.9) | 2.3 (-3.8 to 8.4) | 9.0 (0.2 to 18.1) | | |
| Effect of MedD on plasma total antioxidant capacity (TAC) | 187 | 3.0 | Multiple regression model to predict plasma TAC according to nutritional intervention: | | |
| | | MD + EVOO | MD + Nuts | Control | | |
| | | B coef. (95% CI) | 1.497 (1.005-1.900) p = 0.001 | 1.011 (0.605-1.416) p = 0.001 | 1 | |
| | | | | | | |

BMI: Body Mass Index; CI: Confidence Interval; EVOO: Extra Virgin Olive Oil; FFM: Free Fat Mass; HR: Hazard Ratio; MetS: Metabolic Syndrome; MD: Mediterranean Diet; OR: Odds Ratio; Q: Quartile; TAC: Total Antioxidant Capacity; T2DM: Type 2 Diabetes Mellitus; TFM: Total Fat Mass; TrFM: Truncal Fat Mass; WC: Waist Circumference; %TBW: percentage of Total Body Fat.

Table 3. Characteristics of the RCTs conducted within the frame of the PREDIMED study, investigating the role of Mediterranean Diet (MD) on neurologic disorders and other various conditions.

| Aim of the Study | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study | 1st Author, Journal, Year | Ref. |
|------------------|--------------------|--------------------------|---------------------------|---------------------------|------|
| Neurologic Disorders | | | Adjusted differences versus control (95% CI): | | |
| Effect of MD on cognition | 522 | 6.5 | MD + EVOO | MD + Nuts | Control | Martinez-Lapiscina et al. J. Neurol. Neurosurg Psychiatry 2013 [43] |
| | | | Mini-Mental State Examination | +0.62 (+0.18 to +1.05) p = 0.005 | +0.57 (+0.11 to +1.03) p = 0.015 | 0 (ref.) | |
| | | | Clock Drawing Test | +0.51 (p = 0.001) | +0.33 (+0.003 to +0.67) p = 0.048 | 0 (ref.) | |
| Effect of MD on Mild Cognitive Impairment (MCI) | 268 | 6.5 | MD + EVOO | MD + Nuts | Control | Martinez-Lapiscina et al. J. Nutr. Health Aging 2013 [44] |
| | | | OR (95% CI) for MCI | 0.34 (0.12-0.97) p = 0.044 | 0.56 (0.22-1.43) p = 0.226 | (ref.) | |
Table 3. Cont.

| Aim of the Study | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study | Risk of incident depression: | Risk of very low plasma BDNF concentrations (< 13 μg/mL, 10th percentile) after 3 years: | 1st Author, Journal, Year | Ref. |
|------------------|--------------------|--------------------------|---------------------------|----------------------------|----------------------------------------------------------------|--------------------------|------|
| Effects of MD on depression risk | 3923 | 5.4 | | | | Sánchez-Villegas et al. BMC medicine 2013 | [45] |
| Effect of MD on plasma Brain-Derived Neurotrophic Factor (BDNF) levels | 243 | 3 | | | | Sánchez-Villegas et al. Nutr. Neurosci. 2011 | [46] |
| Other Conditions | | | | | | | |
| MD effect on liver steatosis | 100 | 3.0 | | | | Pintó et al. J. Nutr. 2019 | [47] |
| MD effects on the Fatty Liver Index (FLI) | 276 | 6.0 | | | | Cueto-Galán et al. Med. Clin. 2017 | [48] |

Prevalence of hepatic steatosis, n(%) | MD + EVOO | MD + Nuts | Control | p |
|-------------------------------------|-----------|-----------|---------|---|
| 3 (8.8) | 12 (33.3) | 10 (33.3) | 0.027 |

Mean values of liver fat content | MD + EVOO | MD + Nuts | Control | p |
|----------------------------------|-----------|-----------|---------|---|
| 1.2% | 2.7% | 4.1% | 0.07 |

Values are expressed as n (%) or median (interquartile range).

Mixed linear model

| Changes from baseline in the FLI | MD + EVOO | MD + Nuts |
|-------------------------------|-----------|-----------|
| -3.898 ± 1.873 | 1.679 ± 2.253 |
| -0.239 ± 0.532 | -1.633 ± 0.624 |

ns.: not significant
Table 3. Cont.

| Aim of the Study                      | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study                                      | 1st Author, Journal, Year | Ref.   |
|--------------------------------------|--------------------|--------------------------|----------------------------------------------------------------|---------------------------|--------|
| Incidence of cataract surgery        | 5802               | 5.9                      | Incidence of cataract surgery, HR (95% CI)                      |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                            |                           |        |
|                                      |                    |                          | 1.03 (0.84–1.26) \( p = 0.79 \)                               |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | 1.06 (0.86–1.31) \( p = 0.58 \)                               |                           |        |
|                                      |                    |                          | Differences between post- and pre-intervention values in HDL functional properties: |                           |        |
|                                      |                    |                          | HDL cholesterol/ApoA-I (unitless ratio)                        |                           |        |
|                                      |                    |                          | \(-0.005 (0.020)\)                                            |                           |        |
|                                      |                    |                          | \( p = 0.031 \)                                               |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                           |                           |        |
|                                      |                    |                          | \(-0.010 (0.025)\)                                            |                           |        |
|                                      |                    |                          | \( p < 0.001 \)                                               |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | \(-0.005 (0.026)\)                                            |                           |        |
|                                      |                    |                          | \( p = 0.129 \)                                               |                           |        |
|                                      |                    |                          | Cholesterol efflux capacity (unitless ratio)                   |                           |        |
|                                      |                    |                          | \( 0.019 (0.074) \)                                           |                           |        |
|                                      |                    |                          | \( p = 0.018 \)                                               |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                           |                           |        |
|                                      |                    |                          | \( 0.025 (0.095) \)                                           |                           |        |
|                                      |                    |                          | \( p = 0.013 \)                                               |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | \( 0.018 (0.10) \)                                            |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | HDL cholesterol esterification index (unitless ratio)          |                           |        |
|                                      |                    |                          | \( 0.57 (1.59) \)                                             |                           |        |
|                                      |                    |                          | \( p = 0.007 \)                                               |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                           |                           |        |
|                                      |                    |                          | \( 0.028 (1.32) \)                                            |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | \( 0.16 (1.80) \)                                             |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | Cholesterol ester transfer protein activity (unitless ratio)   |                           |        |
|                                      |                    |                          | \( -0.039 (0.11) \)                                           |                           |        |
|                                      |                    |                          | \( p = 0.008 \)                                               |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                           |                           |        |
|                                      |                    |                          | \( 0.007 \)                                                   |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | \( -0.009 (0.19) \)                                            |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | HDL antioxidant capacity (on LDL lag time) (unitless ratio)    |                           |        |
|                                      |                    |                          | \( 0.41 (0.68) \)                                             |                           |        |
|                                      |                    |                          | \( p < 0.001 \)                                               |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                           |                           |        |
|                                      |                    |                          | \( 0.054 (0.43) \)                                            |                           |        |
|                                      |                    |                          | \( p = 0.018 \)                                               |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | \( 0.018 (0.51) \)                                            |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | HDL oxidation index (unitless ratio)                          |                           |        |
|                                      |                    |                          | \( -0.067 (0.29) \)                                            |                           |        |
|                                      |                    |                          | \( p = 0.028 \)                                               |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                           |                           |        |
|                                      |                    |                          | \( -0.037 (0.21) \)                                            |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | \( -0.072 (0.26) \)                                            |                           |        |
|                                      |                    |                          | \( p = 0.011 \)                                               |                           |        |
|                                      |                    |                          | HDL lag time (unitless ratio)                                  |                           |        |
|                                      |                    |                          | \( 0.13 (0.32) \)                                             |                           |        |
|                                      |                    |                          | \( p = 0.012 \)                                               |                           |        |
|                                      |                    |                          | MD + EVOO vs control                                           |                           |        |
|                                      |                    |                          | \( -0.025 (0.23) \)                                            |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | MD + Nuts vs control                                           |                           |        |
|                                      |                    |                          | \( 0.016 (0.25) \)                                            |                           |        |
|                                      |                    |                          | \( p = \text{ns.} \)                                          |                           |        |
|                                      |                    |                          | Large HDLs (%)                                                 |                           |        |
|                                      |                    |                          | \( 4.34 (9.32) \)                                             |                           |        |
|                                      |                    |                          | \( p < 0.001 \)                                               |                           |        |
|                                      |                    |                          | Hernáez et al.                                                 |                           |        |
|                                      |                    |                          | Circulation                                                   |                           |        |
|                                      |                    |                          | 2017                                                         |                           |        |
|                                      |                    |                          | [50]                                                         |                           |        |
Table 3. Cont.

| Aim of the Study                                                                 | Number of Subjects | Follow-Up Median (Years) | Mean Results of the Study                                                                 | 1st Author, Journal, Year | Ref. |
|---------------------------------------------------------------------------------|-------------------|--------------------------|------------------------------------------------------------------------------------------|---------------------------|------|
| Changes in inflammatory serum biomarkers after 3 and 5 y of follow-up,          |                   |                          | Mean differences (95% CI):                                                                |                           |      |
| Telomere length                                                                |                   |                          | MD + EVOO                                                                                |                           |      |
| MCP-1, pg/mL                                                                    |                   |                          | −1.4 (−1.9, −0.9) *                                                                      |                           |      |
| Δ 3 years                                                                       |                   |                          | −0.7 (−1.3, −0.1) **                                                                     |                           |      |
| Δ 5 years                                                                       |                   |                          | −0.3 (−1.0, 0.4)                                                                         |                           |      |
| IL-6, pg/mL                                                                     |                   |                          | −1.2 (−1.9, −0.6) *                                                                      |                           |      |
| Δ 3 years                                                                       |                   |                          | −1.4 (−2.1, −0.7) **                                                                     |                           |      |
| Δ 5 years                                                                       |                   |                          | −0.1 (−0.9, 0.7)                                                                         |                           |      |
| TNF-a, pg/mL                                                                    |                   |                          | −0.5 (−0.9, −0.2) *                                                                      |                           |      |
| Δ 3 years                                                                       |                   |                          | −0.4 (−0.8, −0.1)                                                                        |                           |      |
| Δ 5 years                                                                       |                   |                          | 0.1 (−0.3, 0.5)                                                                          |                           |      |
| CRP, g/L                                                                        |                   |                          | −0.6 (−0.9, −0.2)                                                                         |                           |      |
| Δ 3 years                                                                       |                   |                          | 0.1 (−0.3, 0.4)                                                                          |                           |      |
| Δ 5 years                                                                       |                   |                          | 0.02 (−0.3, 0.4)                                                                         |                           |      |
| hs-CRP, pg/mL                                                                   |                   |                          | −1.6 (−2.5, −0.7) *                                                                      |                           |      |
| Δ 3 years                                                                       |                   |                          | −0.1 (−1.9, −0.04)                                                                       |                           |      |
| Δ 5 years                                                                       |                   |                          | 0.3 (−0.8, 1.5)                                                                          |                           |      |
| Δ 3 years                                                                       |                   |                          | −1.9 (−2.7, −1.1) *                                                                      |                           |      |
| Δ 5 years                                                                       |                   |                          | −1.2 (−2.0, −0.3)                                                                         |                           |      |
| Δ 3 years                                                                       |                   |                          | −0.4 (−1.4, 0.6)                                                                         |                           |      |
| Δ 5 years                                                                       |                   |                          | −1.8 (−2.4, −1.4) **                                                                     |                           |      |
| Δ 3 years                                                                       |                   |                          | −1.3 (−1.8, −0.1) **                                                                     |                           |      |
| Δ 5 years                                                                       |                   |                          | 1.4 (0.9, 1.7)                                                                            |                           |      |
| Effect of MD on telomere length                                                 |                   |                          | OR (95% CI) for telomere shortening (Δ age adjusted z-score TL ≤ 20th percentile) after 5 y of follow-up, adjusted for sex and initial z-score TL: |                           |      |
| Telomere shortening OR (95% CI)                                                 |                   |                          | MD + EVOO                                                                                |                           |      |
| 1.23 (0.65–2.32)                                                                |                   |                          | MD + Nuts                                                                                 |                           |      |
| 0.95 (1.65–5.29)                                                                |                   |                          | Control                                                                                  |                           |      |
| 1 (ref.)                                                                        |                   |                          |                                           |                           |      |
| Effect of MD on breast cancer incidence                                          |                   |                          | Incidence of invasive breast cancer, HR (95% CI)                                         |                           |      |
| Breast cancer incidence                                                         |                   |                          | MD + EVOO vs control                                                                     |                           |      |
| 0.32 (0.13–0.79)                                                                |                   |                          | MD + Nuts vs control                                                                     |                           |      |
| 0.59 (0.26–1.35)                                                                |                   |                          |                                           |                           |      |

* different from control, \( p < 0.05 \); † different from MedDiet + EVOO, \( p < 0.05 \).
### Table 3. Cont.

| Aim of the Study                                               | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study                                                                 | 1st Author, Journal, Year | Ref. |
|---------------------------------------------------------------|--------------------|--------------------------|------------------------------------------------------------------------------------------|---------------------------|------|
| **MD effect on lipoprotein subfractions**                    | 169                | 1.0                      | 1-year changes in lipoprotein particle by intervention group                              |                           |      |
|                                                               |                    |                          | Means (95% CI):                                                                           |                           |      |
|                                                               |                    |                          | Total VLDL + CM, nmol/L                                                                    | MD + EVOO                 |       |
|                                                               |                    |                          | −2.7 (−9.4; 3.9)                                                                        | −5.9 (−12.7; 0.8)         |       |
|                                                               |                    |                          | Control                                                                                  | 0.9 (−6.2; 7.9)           | 0.391|
|                                                               |                    |                          | Total LDL, nmol/L                                                                        | MD + EVOO                 |       |
|                                                               |                    |                          | −13.8 (−99.4; 71.9)                                                                     | −97.6 (−184.2; −11.1)     | 0.085|
|                                                               |                    |                          | IDL, nmol/L                                                                              | 24.7 (−39.0; −10.3)       | 0.004|
|                                                               |                    |                          | 3.7 (−11.4; 18.8)                                                                        |                           |      |
|                                                               |                    |                          | Total HDL, mmol/L                                                                        | EVOO                     |       |
|                                                               |                    |                          | 0.5 (−0.5; 1.6)                                                                          | 1.1 (0.0; 2.1)            |       |
|                                                               |                    |                          | Mean VLDL size, nm                                                                     | −0.4 (−2.1; 1.3)          |       |
|                                                               |                    |                          | Mean LDL size, nm                                                                       | −1.6 (−3.3; 0.0)          |       |
|                                                               |                    |                          | Mean HDL size, nm                                                                        | 0.2 (0.1; 0.4)            |       |
|                                                               |                    |                          | * Values in a row with different superscript letters are significantly different         |                           |      |
|                                                               |                    |                          | * Measured in 166 participants                                                          |                           |      |
|                                                               |                    | 1.0                      | Multiple linear regressions evaluating the association between changes in plasma NEAC levels, B-coef. (95% CI) adjusted for sex and age: |                           |      |
|                                                               |                    |                          | TRAP, total radical-trapping antioxidant parameter                                        | 47.75 (2.89, 92.61)       |      |
|                                                               |                    |                          | FRAP, ferric reducing antioxidant potential                                               | 38.86 (2.63, 75.09)       |      |
|                                                               |                    |                          | MD + EVOO vs control                                                                     | 50.10 (5.52, 94.68)       |      |
|                                                               |                    |                          | MD + Nuts vs control                                                                    | 56.58 (20.58, 92.58)      |      |
| **Effect of MD on plasma Non-Enzymatic Antioxidant Capacity** | 564                | 1.0                      |                                                                                         |                           |      |
| NEAC                                                          |                    |                          |                                                                                         |                           |      |
|                                                               |                    |                          | **Changes in oxidation markers, mean ± SE:**                                           |                           |      |
|                                                               |                    |                          | MD + EVOO                                                                               | MD + Nuts                 |       |
|                                                               |                    |                          | 8-oxo-dG in mmol/mmol creatinine                                                         | −9.80 (0.58)              |       |
|                                                               |                    |                          | F2-Isoprostanes in ng/mmol creatine                                                      | −11.03 (0.60)             |       |
|                                                               |                    |                          | Control                                                                                 | −1.33 (0.58)              | < 0.001|
|                                                               |                    |                          |                                                                                         |                           |      |
| **Effect of the MD on systemic oxidative biomarkers in MetS**  | 110 female         | 1.0                      |                                                                                         |                           |      |
| individuals                                                   | participants with  |                          |                                                                                         |                           |      |
|                                                               | the diagnosis of   |                          |                                                                                         |                           |      |
|                                                               | MetS               |                          |                                                                                         |                           |      |
|                                                               |                    |                          |                                                                                         |                           |      |

* *p* < 0.001 (vs. control diet)
Table 3. Cont.

| Aim of the Study                                      | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study                                                                                     | 1st Author, Journal, Year |
|-------------------------------------------------------|--------------------|--------------------------|-------------------------------------------------------------------------------------------------------------|---------------------------|
| Effects of MD on apolipoproteins B, A-I, and their ratio | 551                | 0.25                     | Changes from baseline at three-months; differences relative to control diet:                                 | Solá et al. Atherosclerosis 2011 [57] |
|                                                       |                    |                          | **MD + EVOO vs control**                                                                                   |                           |
|                                                       |                    |                          | Total cholesterol (mg/dL) -3.7 (-9.3 to 1.8), \( p = 0.187 \)                                            |                           |
|                                                       |                    |                          | LDL cholesterol, mg/dL -3.2 (-8.4 to 2.0), \( p = 0.230 \)                                               |                           |
|                                                       |                    |                          | HDL cholesterol, mg/dL 2.1 (0.9 to 3.2), \( p = 0.001 \)                                                 |                           |
|                                                       |                    |                          | Non-HDL cholesterol, mg/dL -5.6 (-11.1 to -0.6), \( p = 0.048 \)                                      |                           |
|                                                       |                    |                          | Total/HDL cholesterol, mg/dL -0.27 (-0.43 to -0.11), \( p = 0.001 \)                                  |                           |
|                                                       |                    |                          | LDL/HDL cholesterol ratio -0.20 (-0.32 to -0.07), \( p = 0.002 \)                                      |                           |
|                                                       |                    |                          | Triglycerides (mg/dL) -10.2 (-21.0 to 0.48), \( p = 0.061 \)                                            |                           |
|                                                       |                    |                          | ApoB (mg/dL) -2.9 (-5.6 to -0.08), \( p = 0.044 \)                                                      |                           |
|                                                       |                    |                          | ApoA-I (mg/dL) 3.3 (0.84 to 5.8), \( p = 0.009 \)                                                      |                           |
|                                                       |                    |                          | ApoB/ApoA-I ratio -0.03 (-0.05 to -0.01), \( p = 0.013 \)                                              |                           |
|                                                       |                    |                          | **MD + Nuts vs control**                                                                                  |                           |
|                                                       |                    |                          | Total cholesterol (mg/dL) -6.8 (-12.4 to -1.3), \( p = 0.016 \)                                        |                           |
|                                                       |                    |                          | LDL cholesterol, mg/dL -4.8 (-10.0 to 0.43), \( p = 0.072 \)                                          |                           |
|                                                       |                    |                          | HDL cholesterol, mg/dL 1.21 (0.03 to 2.4), \( p = 0.045 \)                                            |                           |
|                                                       |                    |                          | Non-HDL cholesterol, mg/dL -7.8 (-13.4 to -2.3), \( p = 0.006 \)                                      |                           |
|                                                       |                    |                          | Total/HDL cholesterol, mg/dL -0.24 (-0.39 to -0.08), \( p = 0.003 \)                                  |                           |
|                                                       |                    |                          | LDL/HDL cholesterol ratio -0.15 (-0.28 to -0.03), \( p = 0.017 \)                                      |                           |
|                                                       |                    |                          | Triglycerides (mg/dL) -14.1 (-24.7 to -3.4), \( p = 0.010 \)                                           |                           |
|                                                       |                    |                          | ApoB (mg/dL) -1.83 (-4.6 to 0.91), \( p = 0.189 \)                                                      |                           |
|                                                       |                    |                          | ApoA-I (mg/dL) 1.32 (-1.1 to 3.7), \( p = 0.339 \)                                                      |                           |
|                                                       |                    |                          | ApoB/ApoA-I ratio -0.12 (-0.03 to 0.01), \( p = 0.316 \)                                               |                           |

Changes in the lipid and apolipoprotein composition of VLDL according to baseline levels:

**MD + EVOO**

- VLDL cholesterol: Decrease \( p < 0.05 \)
- Triacylglycerol: Decrease \( p < 0.05 \)
- Triacylglycerol/ApoB ratio: Decrease \( p < 0.05 \)

Numbers not available. No changes were observed in the other two groups.

Perona et al. J. Nutr. Biochem. 2010 [58]
Table 3. Cont.

| Aim of the Study | Number of Subjects | Follow-Up Median (Years) | Main Results of the Study | 1st Author, Journal, Year | Ref. |
|------------------|--------------------|--------------------------|--------------------------|--------------------------|------|
| Phytosterol intake from natural foods association with a cholesterol-lowering effect of MD | 106 | 1.0 | Changes in serum lipids and non-cholesterol sterols, mean changes from baseline (95% CI): | | |
| | | | Lipids (mmol/l) | | | |
| | | | Total cholesterol | MD + EVOO vs control | MD + Nuts vs control | |
| | | | -0.19 (-0.47 to 0.08), p = 0.26 | -0.15 (-0.42 to 0.12), p = 0.51 | |
| | | | LDL cholesterol | | | |
| | | | -0.20 (-0.46 to 0.06), p = 0.20 | -0.27 (-0.53 to -0.01), p = 0.036 | |
| | | | HDL cholesterol | | | |
| | | | 0.02 (-0.07 to 0.11), p = 1.00 | 0.06 (-0.02 to 0.15), p = 0.24 | Escurriol et al. Europ. J. Nutr. 2009 | [59] |
| | | | Non-cholesterol sterols/cholesterol (I M/mM) | | | |
| | | | Lathosterol | 0.10 (-0.45 to 0.25), p = 1.00 | |
| | | | Campesterol | 0.01 (-0.60 to 0.62), p = 1.00 | |
| | | | Sitosterol | 0.15 (-0.27 to 0.58), p = 1.00 | |
| | | | | | | |
| Effects of MD on in vivo lipoprotein oxidation | 372 | 0.25 | Unadjusted 3-months changes. Mean (95% CI): | | |
| | | | MD + EVOO | MD + Nuts | Control | p |
| | | | OxLDL, U/L | -10.1 (-15 to -5.1) | -7.5 (-12 to -2.6) | -2.6 (-8.0 to 2.9) | 0.04 † | Fitó et al. Arch. Int. Med. 2007 | [60] |
| | | | GSH-Px, U/L | -16.4 (-44.6 to 11.8) | -10.4 (-35.9 to 15.1) | -20.1 (-50.6 to 10.4) | 0.35 | |

† Significant differences between MD + EVOO and control diet

ApoA: Apolipoprotein A; ApoB: Apolipoprotein B; EVOO: Extra Virgin Olive Oil; FLI: Frally Liver Index; GSH-Px: Glutathione peroxidase; HDL: High-Density Lipoprotein; HR: Hazard Ratio; hs-CRP: high sensitivity C-Reactive Protein; IDL: Intermediate-Density Lipoprotein; IL-6: Interleukin 6; LDL: Low-Density Lipoprotein; MCP-1: Monocyte Chemotactic Protein 1; MD: Mediterranean Diet; NEAC: Non-Enzymatic Antioxidant Capacity; OR: Odds Ratio; ns: not significant; OxLDL: Oxidized Low-Density Lipoprotein; TNF-α: Tumor Necrosis Factor Alpha; VLDL: Very-Low-Density Lipoprotein.
In the PREDIMED study, a total of 8713 candidates were screened for eligibility, and 7447 of them were enrolled and assigned to one of the three intervention groups (MD + EVOO, MD + Nuts or low-fat diet). Their baseline characteristics according to intervention group are described elsewhere [15]. The exclusion of participants whose randomization procedures were known to have deviated from the protocol did not materially change these results [15]. Participants were followed for a median of 4.8 years (interquartile range: 2.8–5.8). When compliance with diet intervention was examined, an increase in the 14-item MD questionnaire score was observed for the two MD groups during the follow-up period. Substantial differences between the MD groups and the control group in 12 of the 14 items of the questionnaire were observed. Also, biomarkers’ level variations indicated good adherence to the dietary assignments [15]. The main nutrient changes in the MD groups reflected the fat content and composition of the supplementary foods (EVOO or nuts). No relevant diet-related adverse effects were reported. Besides, a little difference in physical activity (assessed with specific questionnaires) among the three groups was observed [15].

As the main objective of the PREDIMED study was to examine the effects of MD on the primary prevention of CVDs, the majority of the RCTs included in our review dealt with CVDs and the related risk factors (Table 1). Estruch et al.’s intention to treat analysis, which included all the 7447 participants, revealed a relative risk reduction of 31% for the MD + EVOO (HR 0.69, 95%CI 0.53, 0.91), and 28% MD + Nuts group (HR 0.72, 95%CI 0.54, 0.95) in the primary composite outcome investigated (including acute myocardial infarction, stroke, or death for CV events), compared to the low-fat control diet group [15]. Moreover, Martínez-González et al., observed that the Hazard Ratio, HR (95% Confidence Interval, CI) for atrial fibrillation in the MD + EVOO group was 0.62 (0.45, 0.85), p < 0.05 [22].

When the effect of MD on diabetes was examined, it was observed that the HR (95% CI) of diabetes incidence was 0.60 (0.43, 0.85) for the subjects following MD + EVOO compared to controls, and 0.82 (0.61, 1.10) for the MD + Nuts group compared to control diet [36]. After the application of the Fine and Gray model for competing risk analysis, the results remained essentially unchanged [61]. Similarly, a subgroup analysis on the PREDIMED population (n = 418), showed a protective effect of the MD either supplemented with EVOO or nuts against the incidence of DM (HR, 95%CI for both MDs versus control 0.47 (0.26–0.87) [62,63]. Another study showed a significant effect of MD on the incidence of diabetic retinopathy: HR (95% CI) 0.59 (0.37, 0.95) for the MD groups [35].

Further trials evaluated the long-term effect of MD on incidence and reversion of MetS. Although there were no significant differences in incidence or reversion HRs by intervention, reversion occurred in 958 (28.2%) participants when considering only those subjects who had MetS at baseline [38]. Salas-Salvadó et al., examined the one-year effect of the MD on metabolic syndrome (MetS) status, as shown in Table 2. They found that, after 1-year follow-up, the MetS prevalence was reduced by a 6.7%, 13.7% and 2% in the MD + EVOO, MD + Nuts and control groups, respectively (MD + Nuts versus control group, p < 0.05). These differences may be due to the variations in incidence rates among subjects without MetS at baseline and in reversion rates among those who had the syndrome at the beginning of the trial [39].

Álvarez-Pérez et al., [41] found that MD had positive effects on body composition and anthropometric measurements in a subsample of the cohort. Nevertheless, no between-group statistically significant differences were found in anthropometric or body composition variables.

After analysing the influence of a Mediterranean dietary pattern on plasma total antioxidant capacity (TAC), the MD + EVOO group showed higher levels of plasma TAC and a reduction in body weight gain [42].

The effects of the MD on cognitive functions were also examined, as shown in Table 3. In a sub-study conducted on 522 participants in Navarra, it was found that the MD improved cognitive function, assessed with the Mini-Mental State Examination and the clock drawing test [43]. Likewise, another study observed that a long-term intervention with an EVOO-rich MD resulted in a better cognitive function in comparison with controls [44].
Toledo et al.’s study, aimed at investigating the incidence of breast cancer on the PREDIMED population, showed a HR (95% CI) of 0.38 (0.16, 0.87) for the MD + EVOO compared to the control group [53]. Other studies examining the effects of the MD on different conditions, other than CVDs, diabetes obesity and cognitive function, are reported in Table 3.

In order to outline the results obtained by the trials analysed in the present review, we calculated the percentage reduction of the risk of various clinical conditions, as shown in Figure 2.

Figure 2. Percentage reduction in the risk of different medical conditions in the PREDIMED Study, according to the group of treatment (MD + EVOO or MD + Nuts) versus the low-fat control diet. The % of risk reduction were computed as: 100−(1−HR)% and it represents the reduction in the instantaneous risk of the above mentioned events at any given point of time, or the reduction in the rate of such events. ns: not significant. MD: Mediterranean Diet; EVOO: Extra Virgin Olive Oil.

The % reduction in the risk of cardiovascular disease (a composite of death for cardiovascular cause, non-fatal acute myocardial infarction, and non-fatal stroke) was 31% (95% CI 47–9%) and 28% (95% CI 46–5%) for MD + EVOO and MD + Nuts groups, respectively [15]. Nevertheless, it is appropriate to observe that, although the % risk of CVD reduction vary according to the dietary intervention, it is not possible to infer that one is better than the other, as shown by the overlapping of the correspondent 95% confidence intervals. For the heart failure (HF), the % reduction observed was not significant in the MD + EVOO nor in the MD + Nuts [21], that is to say, none of the two dietary interventions turned out to be better than the control diet in the risk reduction of the outcome. For the atrial fibrillation the % risk reduction was 38% (95% CI 55–15%) for the MD + EVOO group, while not significant for the MD + Nuts group [22]. The risk reduction of peripheral artery disease was 68% (95% CI 81–44%) and 49% (95% CI 68–17%) for the MD + EVOO and MD + Nuts groups, respectively [29], but the difference between the two dietary interventions was not statistically significant due to the partial overlapping of the 95% CIs. For the probability of remaining free of the glucose-lowering medications, a reduction of 22% (95% CI 38–2%) was observed for the MD + EVOO; no significance was observed for the MD + Nuts group [33]. The reduction in the risk of diabetic retinopathy was significant only for the MD + EVOO group (43%, 95% CI: 67–2%) but not for the MD + Nuts group [35]. Interestingly, the long-term effect of MD on diabetic nephropathy was not beneficial, probably due to the higher salt intake than a hyposodic diet (Table 2) [35]. For the incidence of diabetes mellitus, the risk reduction was 40% (95% CI 57%, 15%) and 18% (39%, 10%) for the MD + EVOO and MD + Nuts intervention groups respectively [36], and the difference between the two dietary approaches did not turn out to be statistically significant. For the depression risk, the MD supplemented with either EVOO or Nuts did not lead to a significant reduction, compared to the control diet. However, a risk reduction was observed in the Nuts + MD group among the diabetic subjects only [45]. Finally, the %
reduction in the risk of breast cancer incidence was 68% (87–21%) for the MD + EVOO group versus the low-fat control diet, while the MD + Nuts did not show to be statistically significant compared to the control group [53].

Overall, the MD + EVOO dietary intervention seemed to have more beneficial effects in terms of % reduction of the risk of different clinical condition. However, in those conditions where both MD + EVOO and MD + Nuts had significative effects compared to the control diet, it is not possible to conclude that the former is better than the latter.

Table 4 shows the percentage reduction from baseline of different continuous variables assessed by the different randomized controlled trials conducted in the scope of the PREDIMED study.
Table 4. Percentage reduction from the baseline of different continuous variables assessed by the randomized clinical trials in the scope of the PREDIMED study.

| Continuous Variable               | Time (yr) | N   | Mean Value at Baseline | Mean Change | % Change from Baseline | p-Value * | N   | Mean Value at Baseline | Mean Change | % Change from Baseline | p-Value * | Ref. |
|-----------------------------------|-----------|-----|------------------------|-------------|------------------------|-----------|-----|------------------------|-------------|------------------------|-----------|------|
| Systolic BP (24 h)                | 1.0       | 78  | 127.3                  | −3.14       | −2.5%                  |           |     | 125.3                  | −2.35       | −1.9%                  |           | [27] |
| Diastolic BP (24 h)               | 1.0       | 78  | 71.8                   | −1.68       | −2.3%                  |           |     | 71.2                   | −1.00       | −1.4%                  |           | [27] |
| BMI, kg/m²                        | 0.25      | 257 | 29.7                   | −0.12       | −0.4%                  |           |     | 29.4                   | −0.09       | −0.3%                  |           | [32] |
| Weight, kg                        | 1.0       | 112 | 77.9                   | −1.0        | −1.3%                  | 0.008     | 102 | 80.3                   | −0.5        | −0.6%                  | 0.197     | [41] |
| BMI, kg/m²                        | 1.0       | 112 | 30.7                   | −0.5        | −1.6%                  | 0.012     | 102 | 31.2                   | −0.5        | −1.6%                  | 0.314     | [41] |
| WC, cm                            | 1.0       | 112 | 100.5                  | −1.1        | −1.0%                  | 0.046     | 102 | 102.6                  | −2.3        | −2.2%                  | <0.001    | [41] |
| Urinary albumin, mg/L             | 1.0       | 310 | 5.0                    | 0.55        | 11.0%                  |           |     | 5.1                    | −2.85       | −55.9%                  |           | [28] |
| Urinary albumin/creatinine, mg/g   | 1.0       | 310 | 7.09                   | 1.13        | 15.9%                  |           |     | 7.21                   | −1.62       | −22.5%                  |           | [28] |
| Intima-media thickness, mm        | 1.0       | 66  | 0.825                  | −0.016      | −1.9%                  |           |     | 0.854                  | −0.033      | −3.8%                  |           | [31] |
| Total cholesterol, mg/dL          | 0.25      | 181 | 219.7                  | −3.7        | −1.7%                  | ns.       | 193 | 216.7                  | −6.8        | −3.1%                  | <0.05     | [57] |
| Oxidized LDL, U/L                 | 1.0       | 310 | 74.3                   | −9.75       | −13.1%                 |           |     | 71.1                   | −5.68       | −8.0%                  |           | [28] |
| Ox-LDL, U/L                       | 0.25      | 123 | 77.9                   | −10.1       | −13.0%                 |           |     | 74.4                   | −7.5        | −10.1%                 |           | [60] |
| LDL cholesterol, mg/dL            | 0.25      | 181 | 146.2                  | −4.3        | −2.9%                  | <0.05     | 193 | 141.6                  | −5.9        | −4.2%                  | <0.05     | [57] |
| HDL cholesterol, mg/dL            | 0.25      | 181 | 51.9                   | 1.8         | +3.5%                  | <0.05     | 193 | 53.9                   | 0.95        | 1.8%                   | <0.05     | [57] |
| Non-HDL cholesterol, mg/dL        | 0.25      | 181 | 174.2                  | −5.4        | −3.1%                  | <0.05     | 193 | 169.6                  | −7.6        | −4.5%                  | <0.05     | [57] |
| Total/HDL cholesterol, mg/dL      | 0.25      | 181 | 5.0                    | −0.24       | −4.8%                  | <0.05     | 193 | 4.8                    | −0.20       | −4.2%                  | <0.05     | [57] |
| LDL/HDL cholesterol ratio         | 0.25      | 181 | 3.4                    | −0.20       | −5.9%                  | <0.05     | 193 | 3.1                    | −0.15       | −4.8%                  | <0.05     | [57] |
| Triglycerides, mg/dL              | 0.25      | 181 | 139.9                  | −4.8        | −3.4%                  | ns.       | 193 | 138.2                  | −8.62       | −6.2%                  | <0.05     | [57] |
| ApoB, mg/dL                       | 0.25      | 181 | 102                    | −2.8        | −4.4%                  | <0.05     | 193 | 101                    | −1.7        | −1.4%                  | ns.       | [57] |
| ApoA-I, mg/dL                     | 0.25      | 181 | 135                    | 2.5         | +3.2%                  | <0.05     | 193 | 134                    | 0.16        | 1.4%                   | ns.       | [57] |
| ApoB/ApoA-I ratio                 | 0.25      | 181 | 0.78                   | −0.03       | −6.2%                  | <0.05     | 193 | 0.78                   | −0.009      | −1.2%                  | ns.       | [57] |
| Lipoprotein(a), mg/dL             | 1.0       | 310 | 24.8                   | 0.68        | 2.7%                   |           |     | 24.4                   | 2.23        | 9.1%                   |           | [28] |
| NT-proBNP, pg/mL                  | 1.0       | 310 | 572                    | −27.7       | −4.8%                  |           |     | 362                    | −42.0       | −7.4%                  |           | [28] |
| GSH-Px, U/L                       | 0.25      | 123 | 626                    | −16.4       | −2.6%                  |           |     | 613                    | −10.4       | −1.7%                  |           | [60] |
Table 4. Cont.

| Continuous Variable          | Time (yr) | N  | Mean Value at Baseline | Mean Change | % Change from Baseline | p-Value * | N  | Mean Value at Baseline | Mean Change | % Change from Baseline | p-Value * | Ref. |
|------------------------------|-----------|----|------------------------|-------------|------------------------|-----------|----|------------------------|-------------|------------------------|-----------|------|
| sVCAM-1, ng/mL               | 1.0       | 55 | 872                    | −138        | −15.8%                 | 0.02      | 55 | 935                    | −208        | −22.2%                 | 0.001     | [26] |
| sICAM-1, ng/mL               | 1.0       | 55 | 437                    | −220        | −50.3%                 | <0.001    | 55 | 394                    | −30.3       | −7.7%                  | 0.20      | [26] |
| sE-SEL, ng/mL                | 1.0       | 55 | 28.6                   | −1.7        | −5.9%                  | 0.26      | 55 | 33.0                   | −4.7        | −14.2%                 | 0.003     | [26] |
| MCP-1, pg/mL vs. baseline    | 3.0       | 55 | 4.3                    | −1.4        | −32.6%                 | <0.05     | 55 | 4.6                    | −0.7        | −15.2%                 | <0.05     | [51] |
| IL-6, pg/mL vs. baseline     | 3.0       | 55 | 1.3                    | −0.5        | −38.4%                 | <0.05     | 55 | 1.4                    | −0.4        | −28.6%                 | <0.05     | [51] |
| TNF-α, pg/mL vs. baseline    | 3.0       | 55 | 3.6                    | 1.6         | −44.4%                 | <0.05     | 55 | 3.6                    | −1.0        | −27.8%                 | <0.05     | [51] |
| Hs-CRP, g/L vs. baseline     | 3.0       | 55 | 3.7                    | −1.8        | −48.6%                 | <0.05     | 55 | 3.5                    | −1.3        | −37.1%                 | <0.05     | [51] |
| 8-oxo-dG in mmol/mmol creatinine | 1.0     | 38 | 20.24                  | −9.80       | −48.4%                 | <0.001    | 35 | 19.98                  | −11.03      | −55.2%                 | <0.001    | [56] |
| F2-Isoprostanes in ng/mmol creatine | 1.0  | 38 | 76.15                  | −13.71      | −18.0%                 | -         | 35 | 97.40                  | −14.82      | −15.2%                 | -         | [56] |

* where not specified, p-value is not available due to the computation of the % reduction from baseline of the variables from the available data. ns.: not statistically significant. BMI: Body Mass Index; BP: Blood Pressure; GSH-px: glutathione peroxidase; HDL: High Density Lipoprotein; hs-CRP: high sensitivity C-Reactive Protein; IL-6: Interleukin 6; LDL: Low Density Lipoprotein; MCP-1: Monocyte Chemotactic Protein 1; NT-proBNP: N-Terminal-pro-Brain Natriuretic Peptide; sE-SEL: soluble E Seclectin; sICAM: soluble Intercellular Adhesion Molecule; sVCAM: soluble Vascular Cell Adhesion Molecule; TNF-α: Tumor Necrosis Factor α; WC: Waist Circumference.
4. Discussion

The RCTs conducted within the frame of the PREDIMED study are the study designs able to best describe the effects of the MD on CVDs and other secondary health outcomes, in terms of sample size, duration of the intervention and follow-up. Nevertheless, in a comprehensive review evaluating the epidemiological and molecular aspects of the MD for non-PREDIMED articles, it was emphasized that only few of them evaluated hard endpoints, and that most of the studies had a sample size smaller than 200 people [1]. It was specified that the most convenient study in terms of number of participants, duration of the intervention and number of publications produced was the PREDIMED study [1]. In the present review, 44 RCTs of PREDIMED study met our inclusion criteria, and the majority of them presented a sample size larger than 200 subjects. The aim of the present review is to summarize the results of RCTs in the PREDIMED study, mainly related to cardiovascular diseases, diabetes, obesity, metabolic syndrome and many other important conditions, and to synthetize the best evidence available.

The results of the PREDIMED study reported in 2013 have been partially retracted due to protocol deviations, mainly regarding the randomization process. Nevertheless, after re-analyzing the collected data with the appropriate corrections (omitting 1588 participants whose study group assignment was known or suspected to have deviated from the protocol), the results obtained were similar [15].

When both the MD groups (MD + EVOO and MD + Nuts) were examined, the MD nutrition model used in the PREDIMED study turned out to potentially reduce the number of hard clinical events in a relatively short time [18]. Firstly, in 2013 it was reported that both intervention groups showed approximately a 30% reduction in the rate of major CV events (myocardial infarction, stroke or death for CV causes), compared to the control group, after a median follow-up of 4.8 years [13].

The epidemiological evidence of the CVD protection provided by the adherence to the MD is strong. A meta-analysis by Liyanage et al., found that the MD was associated with a 37% relative reduction \( p < 0.001 \) in the risk of major CV events [64]. These findings are in agreement with the results of the trials included in the present review, which showed positive effects of the MD on atrial fibrillation [22], and peripheral artery disease [29]. The underlying mechanisms of protection against CVD provided by the MD can be attributed to the abundance of antioxidant and anti-inflammatory molecules in its individual components such as fruits and vegetables, olive oil, nuts, whole grains, fish and red wine, although the specific protective mechanisms of MD on CVDs are not completely understood. One of the hypotheses suggests a possible role of the cell redox state in the modulation of the enzymatic systems related to the antioxidant capacity. Additionally, nutrients have the ability to regulate gene expression and protein synthesis. As reported by nutrigenomic studies, MD can play a role against the expression of several proatherogenic genes involved in vascular inflammation, foam cell formation and thrombosis [18].

As secondary endpoints of the PREDIMED study, diabetes incidence and MetS status were also assessed. The largest trial on the incidence of type 2 diabetes mellitus (T2DM) in the primary prevention PREDIMED study, reported a significant reduction of the incidence in both the intervention groups [36]. Moreover, the results of prospective cohort studies contributing to estimate T2DM risk according to different levels of MD adherence provided additional and consistent evidence [65]. Their results support the protective role of the MD against T2DM, with overall risk reductions ranging from 12% to 83% for subjects closely adhering to the MD compared to those reporting the lowest adherence, after adjusting for several confounders [65]. The authors also observed that higher adherence to the MD had a beneficial role in the prevention and treatment of MetS and its components [65]. In the PREDIMED study, although no differences in the onset of MetS were observed among the three groups, participants in the MD + EVOO and MD + Nuts were more likely to present disease reversion, if compared to the control group [38]. Esposito et al., (2015) specified that two meta-analyses assessed the relationship between adherence to a MD and future incidence of diabetes. According to their report, the analyses are consistent with a significant reduction, ranging from 19% to 23%, of new diabetes diagnosis associated with greater adherence to the MD [66]. In the Framingham Heart Study Offspring Cohort,
1918 participants free of the condition at baseline were followed for seven years, and participants in the highest quintile category of the Mediterranean-style dietary pattern score had a lower incidence of metabolic syndrome than those in the lowest quintile category \( (p = 0.01) \) \[67\]. It is thought that highly important bioactive components of the MD such as unsaturated fatty acids, complex carbohydrates and fibre, vegetable protein, non-sodium minerals, phytosterols and polyphenols interact synergistically to advantageously affect various metabolic pathways at risk of MetS, T2DM and CVD \[65\].

The role of MD in the protection against cognitive decline, is being supported by growing evidence. Although the majority of the available studies in the issue present a longitudinal or a cross-sectional design, they point out the protective role of MD on cognitive impairment, cognitive function and decline \[68\].

Among the secondary outcomes of the PREDIMED study, the incidence of breast cancer was assessed. To date, the evidence on the role of Mediterranean diet in the onset of this neoplasm is still limited; nevertheless, the findings of Toledo et al.’s study (2015) are in agreement with the available literature \[69,70\], and are statistically strengthened by its prospective, randomized and controlled design.

As a result, with the exception of the PREDIMED study, most of the studies on MD appear to be observational studies or short-term trials. Among many issues, the findings of the PREDIMED study include a large number of randomized controlled trials that provide a higher level of scientific evidence than cohort studies and represent the gold standard to clarify the actual effects of this intervention. The PREDIMED trial is a milestone of nutrition intervention that indicated with powerful evidence the benefits of the traditional MD in the primary prevention of CVD in individuals at high risk. As secondary endpoints of the PREDIMED study, it was observed that MD interventions could protect against diabetes in participants without diabetes and figure out a role in preventing or managing MetS and certain metabolic abnormalities that predicts diabetes and cardiometabolic risk.

5. Conclusions

In conclusion, the contribution of the PREDIMED study as a commendable dietary intervention study is certain. This trial present as primary endpoint a composite of CV events and, in the frame of the study, sub-group analyses have been performed to assess various secondary outcomes. The scope of this review was to sum up the experimental outcomes of those studies. Randomized controlled trials within the scope of the PREDIMED study demonstrated the risk-reducing effects on major health problems and risk factors as well as the current and known effects of the Mediterranean diet. When the diet is considered as the main determinant of many health outcomes, we testify the Mediterranean diet as a comprehensive diet model that overcomes a single food or single nutrient approach.

Author Contributions: L.S.-M. and D.K. conceived the original idea for the review. L.S.-M. drafted the aim of the work and the analytical plan. D.K. organized and conducted the literature research and the analysis of the selected papers, preparing the first draft of the manuscript. L.T. critically revised the whole manuscript, checking the selection process and the papers included. Finally, she set up the tables and the final English version of the manuscript. All authors contributed to the critical appraisal of the review and approved the final version.

Conflicts of Interest: Lluís Serra-Majem is the Editor in Chief of Nutrients. The other authors have no conflict of interest to declare.

References

1. Serra-Majem, L.; Roman-Vinas, B.; Sánchez-Villegas, A.; Guasch-Ferré, M.; Corella, D.; La Vecchia, C. Benefits of the Mediterranean diet: Epidemiological and molecular aspects. *Mol. Asp. Med.* **2019**, *67*, 1–55. [CrossRef] [PubMed]
2. Trichopoulou, A.; Martinez-González, M.A.; Tong, T.Y.; Forouhi, N.G.; Khandelwal, S.; Prabhakaran, D.; Mozaffarian, D.; de Lorgeril, M. Definitions and potential health benefits of the Mediterranean diet: Views from experts around the world. *BMC Med.* **2014**, *12*, 112. [CrossRef] [PubMed]
3. Trichopoulou, A.; Lagiou, P. Healthy traditional Mediterranean diet: An expression of culture, history, and lifestyle. *Nutr. Rev.* 1997, 55, 383–389. [CrossRef] [PubMed]

4. Willett, W.C.; Sacks, F.; Trichopoulou, A.; Drescher, G.; Ferro-Luzzi, A.; Helsing, E.; Trichopoulou, D. Mediterranean diet pyramid: A cultural model for healthy eating. *Am. J. Clin. Nutr.* 1995, 61, 1402S–1406S. [CrossRef]

5. Tosti, V.; Bertozzi, B.; Fontana, L. Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms. *J. Gerontol. Ser. A* 2018, 73, 318–326. [CrossRef]

6. Bach-Faig, A.; Berry, E.M.; Lairon, D.; Reguant, J.; Trichopoulou, A.; Dernini, S.; Medina, F.X.; Battino, M.; Belahsen, R.; Miranda, G.; et al. Mediterranean diet pyramid today. Science and cultural updates. *Public Health Nutr.* 2011, 14, 2274–2284. [CrossRef]

7. Keys, A.; Mierassi, A.; Karvonen, M.J.; Aravanis, C.; Blackburn, H.; Buzina, R.; Djordjevic, B.; Dontas, A.; Fidanza, F.; Keys, M.H. The diet and 15-year death rate in the seven countries study. *Am. J. Epidemiol.* 1986, 124, 903–915. [CrossRef]

8. Trichopoulou, A. Traditional Mediterranean diet and longevity in the elderly: A review. *Public Health Nutr.* 2004, 7, 943–947. [CrossRef] [PubMed]

9. Serra-Majem, L.; Roman, B.; Estruch, R. Scientific evidence of interventions using the Mediterranean diet: A systematic review. *Nutr. Res.* 2006, 64, S27–S47. [CrossRef]

10. Dinu, M.; Pagliai, G.; Casini, A.; Sofi, F. Mediterranean diet and multiple health outcomes: An umbrella review of meta-analyses of observational studies and randomised trials. *Eur. J. Clin. Nutr.* 2018, 72, 30–43. [CrossRef]

11. Kris-Etherton, P.; Eckel, R.H.; Howard, B.V.; St. Jeor, S.; Bazzarre, T.L. AHA Science Advisory: Lyon diet association Step I dietary pattern on cardiovascular disease. *Circulation* 2001, 103, 1823–1825. [CrossRef] [PubMed]

12. Martínez-González, M.A.; Bes-Rastrollo, M.; Serra-Majem, L.; Lairon, D.; Estruch, R.; Trichopoulou, A. Mediterranean food pattern and the primary prevention of chronic disease: Recent developments. *Nutr. Rev.* 2009, 67, S111–S116. [CrossRef] [PubMed]

13. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.I.; Corella, D.; Arós, F. Primary prevention of cardiovascular disease with a Mediterranean diet. *N. Engl. J. Med.* 2013, 368, 1279–1290. [CrossRef] [PubMed]

14. PREDIMED Study. Available online: http://www.predimed.es (accessed on 24 July 2019).

15. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.I.; Corella, D.; Arós, F.; Gómez-Grau, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. PREDIMED Study Investigators, Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N. Engl. J. Med.* 2018, 378, e34. [CrossRef]

16. Martínez-González, M.A.; Corella, D.; Salas-Salvadó, J.; Ros, E.; Covas, M.I.; Fiol, M.; Warnberg, J.; Arós, F.; Ruiz-Gutiérrez, V.; Lamuela-Raventos, R.M.; et al. Cohort profile: Design and methods of the PREDIMED study. *Int. J. Epidemiol.* 2012, 41, 377–385. [CrossRef]

17. Martínez-González, M.A.; García-Arellano, A.; Toledo, E.; Salas-Salvadó, J.; Buil-Cosiales, P.; Corella, D.; Covas, M.I.; Schroder, H.; Arós, F.; Gomez-Gracia, E.; et al. PREDIMED Study Investigators, A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subjects: The PREDIMED trial. *PLoS ONE* 2012, 7, e43134. [CrossRef]

18. Martínez-González, M.A.; Salas-Salvadó, J.; Estruch, R.; Corella, D.; Fito, M.; Ros, E. PREDIMED Investigators, Benefits of the Mediterranean Diet: Insights From the PREDIMED Study. *Prog. Cardiovasc. Dis.* 2015, 58, 50–60. [CrossRef]

19. Sackett, D.L.; Rosenberg, W.M.; Gray, J.M.; Haynes, R.B.; Richardson, W.S. Evidence based medicine: What it is and what it isn’t. *BMJ* 1996, 312, 71–72. [CrossRef]

20. Papadaki, A.; Martínez-González, M.A.; Alonso-Gomez, A.; Rekondo, J.; Salas-Salvadó, J.; Corella, D.; Ros, E.; Fito, M.; Estruch, R.; Lapetra, J.; et al. Mediterranean diet and risk of heart failure: Results from the PREDIMED randomized controlled trial. *Eur. J. Heart Fail.* 2017, 19, 1179–1185. [CrossRef]

21. Papadaki, A.; Martínez-González, M.A.; Alonso-Gomez, A.; Rekondo, J.; Salas-Salvadó, J.; Corella, D.; Ros, E.; Fito, M.; Estruch, R.; Lapetra, J.; et al. Erratum for Mediterranean diet and risk of heart failure: Results from the PREDIMED randomized controlled trial. *Eur. J. Heart Fail.* 2019, 21, 389–391. [CrossRef]
22. Martínez-González, M.A.; Toledo, E.; Arós, F.; Fiol, M.; Corella, D.; Salas-Salvadó, J.; Ros, E.; Covas, M.I.; Fernandez-Crehuet, J.; Lapetra, J.; et al. PREDIMED Investigators. Extravirgin olive oil consumption reduces risk of atrial fibrillation: The PREDIMED (Prevencion con Dieta Mediterranea) trial. *Circulation* 2014, 130, 18–26. [CrossRef] [PubMed]

23. Hernández, A.; Castañeda, O.; Goday, A.; Ros, E.; Pintó, X.; Estruch, R.; Salas-Salvadó, J.; Corella, D.; Arós, F.; Serra-Majem, L.; et al. The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk individuals: A randomized controlled trial. *Mol. Nutr. Food Res.* 2017, 61, 1601015. [CrossRef] [PubMed]

24. Storniolo, C.E.; Casillas, R.; Bullo, M.; Castaner, O.; Ros, E.; Saez, G.T.; Toledo, E.; Estruch, R.; Ruiz-Gutiérrez, V.; Fitó, M.; et al. A Mediterranean diet supplemented with extra virgin olive oil or nuts improves endothelial markers involved in blood pressure control in hypertensive women. *Eur. J. Nutr.* 2017, 56, 89–97. [CrossRef] [PubMed]

25. Medina-Remon, A.; Tresserra-Rimbau, A.; Pons, A.; Tur, J.A.; Martorell, M.; Ros, E.; Buil-Cosiales, P.; Sacanella, E.; Covas, M.I.; Corella, D.; et al. Effects of total dietary polyphenols on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. The PREDIMED randomized trial. *Nutr. Metab. Cardiovasc. Dis.* 2015, 25, 60–67. [CrossRef]

26. Casas, R.; Sacanella, E.; Urpi-Sardà, M.; Chiva-Blanch, G.; Ros, E.; Martínez-González, M.-A.; Covas, M.-L; Lamuela-Raventos, R.M.; Salas-Salvadó, J.; Fiol, M.; et al. The effects of the mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial. *PLoS ONE* 2014, 9, e100084. [CrossRef]

27. Doménech, M.; Roman, P.; Lapetra, J.; García de la Corte, F.J.; Sala-Vila, A.; de la Torre, R.; Corella, D.; Salas-Salvadó, J.; Ruiz-Gutiérrez, V.; Lamuela-Raventós, R.M.; et al. Mediterranean diet reduces 24-h ambulatory blood pressure, blood glucose, and lipids: One-year randomized, clinical trial. *Hypertension* 2014, 64, 69–76. [CrossRef]

28. Fitó, M.; Estruch, R.; Salas-Salvadó, J.; Martínez-González, M.A.; Arós, F.; Vila, J.; Corella, D.; Díaz, O.; Saez, G.; de la Torre, R.; et al. PREDIMED Study Investigators, Effect of the Mediterranean diet on heart failure biomarkers: A randomized sample from the PREDIMED trial. *Eur. J. Heart. Fail.* 2014, 16, 543–550. [CrossRef] [PubMed]

29. Ruiz-Canela, M.; Estruch, R.; Corella, D.; Salas-Salvadó, J.; Martínez-González, M.A. Association of Mediterranean diet with peripheral artery disease: The PREDIMED randomized trial. *Jama* 2014, 311, 415–417. [CrossRef]

30. Toledo, E.; Hu, F.B.; Estruch, R.; Buil-Cosiales, P.; Corella, D.; Salas-Salvadó, J.; Covas, M.I.; Arós, F.; Gómez-Gracia, E.; Fiol, M.; et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: Results from a randomized controlled trial. *BMJ Med.* 2013, 11, 207. [CrossRef]

31. Murie-Fernandez, M.; Irimia, P.; Toledo, E.; Martínez-Vila, E.; Buil-Cosiales, P.; Serrano-Martínez, M.; Ruiz-Gutiérrez, V.; Ros, E.; Estruch, R.; Martínez-González, M.A. PREDIMED Investigators, Carotid intima-media thickness changes with Mediterranean diet: A randomized trial (PREDIMED-Navarra). *Atherosclerosis* 2011, 219, 158–162. [CrossRef]

32. Estruch, R.; Martínez-González, M.A.; Corella, D.; Salas-Salvadó, J.; Ruiz-Gutiérrez, V.; Covas, M.I.; Fiol, M.; Gómez-Gracia, E.; López-Sabater, M.C.; Vinyoles, E.; et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: A randomized trial. *Ann. Int. Med.* 2006, 145, 1–11. [CrossRef]

33. Basterra-Gortari, F.J.; Ruiz-Canela, M.; Martínez-González, M.A.; Babio, N.; Sorlí, J.V.; Fitó, M.; Ros, E.; Gómez-Gracia, E.; Fiol, M.; Lapetra, J.; et al. PREDIMED Study Investigators, Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial. *Diabetes Care* 2019, 42, 1390–1397. [CrossRef]

34. Díaz-López, A.; Babio, N.; Martínez-González, M.A.; Corella, D.; Amor, A.J.; Fitó, M.; Estruch, R.; Arós, F.; Gómez-Gracia, E.; Fiol, M. Mediterranean diet, retinopathy, nephropathy, and microvascular diabetes complications: A post hoc analysis of a randomized trial. *Diabetes Care* 2015, 38, 2134–2141. [CrossRef]

35. Díaz-López, A.; Babio, N.; Martínez-González, M.A.; Corella, D.; Amor, A.J.; Fitó, M.; Estruch, R.; Arós, F.; Gómez-Gracia, E.; Fiol, M.; et al. PREDIMED Study Investigators, Erratum. Mediterranean Diet, Retinopathy, Nephropathy, and Microvascular Diabetes Complications: A Post Hoc Analysis of a Randomized Trial. *Diabetes Care* 2018, 41, 2260–2261. [CrossRef]
Nutrients 2019, 11, 2991

36. Salas-Salvadó, J.; Bulló, M.; Estruch, R.; Ros, E.; Covas, M.I.; Ibarrola-Jurado, N.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; et al. PREDIMED Study Investigators, Prevention of diabetes with Mediterranean diets. Ann. Int. Med. 2014, 160, 1–10. [CrossRef]

37. Sureda, A.; Bibiloni, M.D.; Martorell, M.; Buil-Cosiales, P.; Marti, A.; Pons, A.; Tur, J.A.; Martínez-González, M.A. PREDIMED Study Investigators, Mediterranean diets supplemented with virgin olive oil and nuts enhance plasmatic antioxidant capabilities and decrease xanthine oxidase activity in people with metabolic syndrome: The PREDIMED study. Mol. Nutr. Food. Res. 2016, 60, 2654–2664. [CrossRef]

38. Babio, N.; Toledo, E.; Estruch, R.; Ros, E.; Martínez-González, M.A.; Castañer, O.; Bulló, M.; Corella, D.; Arós, F.; Gómez-Gracia, E.; et al. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. CMAJ 2014, 186, E649–E657. [CrossRef]

39. Salas-Salvadó, J.; Fernández-Ballart, J.; Ros, E.; Martínez-González, M.-A.; Fitó, M.; Estruch, R.; Corella, D.; Fiol, M.; Gómez-Gracia, E.; Arós, F. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: One-year results of the PREDIMED randomized trial. Arch. Int. Med. 2008, 168, 2449–2458. [CrossRef]

40. Estruch, R.; Martínez-González, M.A.; Corella, D.; Salas-Salvadó, J.; Fitó, M.; Chiva-Blanch, G.; Fiol, M.; Gómez-Gracia, E.; Arós, F.; Lapetra, J.; et al. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: A prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. Lancet Diabetes Endocrinol. 2019, 7, e6–e17. [CrossRef]

41. Álvarez-Pérez, J.; Sánchez-Villegas, A.; Díaz-Benitez, E.M.; Ruano-Rodriguez, C.; Corella, D.; Martínez-González, M.A.; Estruch, R.; Salas-Salvadó, J.; Serra-Majem, L. PREDIMED Study Investigators, Influence of a Mediterranean Dietary Pattern on Body Fat Distribution: Results of the PREDIMED-Canarias Intervention Randomized Trial. J. Am. Coll. Nutr. 2016, 35, 568–580. [CrossRef]

42. Razquin, C.; Martínez, J.A.; Martínez-González, M.A.; Mitjavila, M.T.; Estruch, R.; Martí, A. A 3 years follow-up of a Mediterranean diet rich in virgin olive oil is associated with high plasma antioxidant capacity and reduced body weight gain. Eur. J. Clin. Nutr. 2009, 63, 1387–1393. [CrossRef] [PubMed]

43. Martínez-Lapiscina, E.H.; Clavero, P.; Toledo, E.; Estruch, R.; Salas-Salvadó, J.; San Julián, B.; Sanchez-Tainta, A.; Ros, E.; Valls-Pedret, C.; Martínez-González, M.A. Mediterranean diet improves cognition: The PREDIMED-NAVARRA randomised trial. J. Neurol. Neurosurg. Psychiatry 2013, 84, 1318–1325. [CrossRef] [PubMed]

44. Martínez-Lapiscina, E.H.; Clavero, P.; Toledo, E.; San Julian, B.; Sanchez-Tainta, A.; Corella, D.; Lamuela-Raventos, R.; Martínez, J.; Martínez-González, M.A. Virgin olive oil supplementation and long-term cognition: The PREDIMED-NAVARRA randomized, trial. J. Nutr. Health Aging 2013, 17, 544–552. [CrossRef] [PubMed]

45. Sánchez-Villegas, A.; Martínez-González, M.A.; Estruch, R.; Salas-Salvadó, J.; Corella, D.; Covas, M.I.; Arós, F.; Romaguera, D.; Gómez-Gracia, E.; Lapetra, J.; et al. Mediterranean dietary pattern and depression: The PREDIMED randomized trial. BMC Med. 2013, 11, 208. [CrossRef] [PubMed]

46. Sánchez-Villegas, A.; Galbete, C.; Martínez-González, M.A.; Martínez, J.A.; Razquin, C.; Salas-Salvadó, J.; Estruch, R.; Buil-Cosiales, P.; Martí, A. The effect of the Mediterranean diet on plasma brain-derived neurotrophic factor (BDNF) levels: The PREDIMED-NAVARRA randomized trial. Nutr. Neurosci. 2011, 14, 195–201. [CrossRef]

47. Pintó, X.; Fanlo-Maresma, M.; Corbella, E.; Corbella, X.; Mitjavila, M.T.; Moreno, J.J.; Casas, R.; Estruch, R.; Corella, D.; Bulló, M.; et al. A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk. J. Nutr. 2019, 149, 1920–1929. [CrossRef]

48. Cueto-Galán, R.; Barón, F.J.; Valdivielso, P.; Pintó, X.; Corbella, E.; Gómez-Gracia, E.; Wärnberg, J. Changes in fatty liver index after consuming a Mediterranean diet: 6-Year follow-up of the PREDIMED-Malaga trial. Med. Clin. 2017, 148, 435–443. [CrossRef]

49. García-Layana, A.; Ciufo, G.; Toledo, E.; Martínez-González, M.; Corella, D.; Fitó, M.; Estruch, R.; Gómez-Gracia, E.; Fiol, M.; Lapetra, J.; et al. The effect of a Mediterranean diet on the incidence of cataract surgery. Nutrients 2017, 9, 453. [CrossRef]
50. Hernández, Á.; Castañer, O.; Elosua, R.; Pintó, X.; Estruch, R.; Salas-Salvadó, J.; Corella, D.; Arós, F.; Serra-Majem, L.; Fiol, M.; et al. Mediterranean diet improves high-density lipoprotein function in high-cardiovascular-risk individuals: A randomized controlled trial. *Circulation* 2017, 135, 633–643. [CrossRef]

51. Casas, R.; Sacanella, E.; Urpí-Sardà, M.; Corella, D.; Castaño, O.; Lamuela-Raventós, R.-M.; Salas-Salvadó, J.; Martínez-González, M.-A.; Ros, E.; Estruch, R. Long-term immunomodulatory effects of a Mediterranean diet in adults at high risk of cardiovascular disease in the Prevención con Dieta MEDiterránea (PREDIMED) randomized controlled trial. *J. Nutr.* 2016, 146, 1684–1693. [CrossRef]

52. García-Calzón, S.; Martínez-González, M.A.; Razquin, C.; Arós, F.; Lapetra, J.; Martínez, J.A.; Zalba, G.; Martí, A. Mediterranean diet and telomere length in high cardiovascular risk subjects from the PREDIMED-NAVARRA study. *Clin. Nutr.* 2016, 35, 1399–1405. [CrossRef] [PubMed]

53. Toledo, E.; Salas-Salvadó, J.; Donat-Vargas, C.; Buil-Cosiales, P.; Estruch, R.; Ros, E.; Corella, D.; Fitó, M.; Hu, F.B.; Arós, F.; et al. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDIMED trial: A randomized clinical trial. *JAMA Intern. Med.* 2015, 175, 1752–1760. [CrossRef] [PubMed]

54. Damasceno, N.R.; Sala-Vila, A.; Cofán, M.; Pérez-Heras, A.M.; Fitó, M.; Ruiz-Gutiérrez, V.; Martínez-González, M.-Á.; Corella, D.; Arós, F.; Estruch, R.; et al. Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. *Atherosclerosis* 2013, 230, 347–353. [CrossRef] [PubMed]

55. Zamora-Ros, R.; Serafini, M.; Estruch, R.; Lamuela-Raventós, R.; Martínez-González, M.; Salas-Salvadó, J.; Fiol, M.; Lapetra, J.; Arós, F.; Covas, M.; et al. PREDIMED Study Investigators, Mediterranean diet and non enzymatic antioxidant capacity in the PREDIMED study: Evidence for a mechanism of antioxidant tuning. *Nutr. Metab. Cardiovasc. Dis.* 2013, 23, 1167–1174. [CrossRef] [PubMed]

56. Mitjavila, M.T.; Fandos, M.; Salas-Salvadó, J.; Covas, M.-I.; Borrego, S.; Estruch, R.; Lamuela-Raventós, R.; Corella, D.; Martínez-González, M.A.; Sánchez, J.M.; et al. The Mediterranean diet improves the systemic lipid and DNA oxidative damage in metabolic syndrome individuals. A randomized, controlled, trial. *Clin. Nutr.* 2013, 32, 172–178. [CrossRef] [PubMed]

57. Solá, R.; Fitó, M.; Estruch, R.; Salas-Salvadó, J.; Corella, D.; de la Torre, R.; Muñoz, M.A.; Lopez-Sabater Mdél, C.; Martínez-González, M.A.; Arós, F.; et al. Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: A randomized, controlled trial. *Atherosclerosis* 2011, 218, 174–180. [CrossRef]

58. Perona, J.S.; Covas, M.-I.; Fitó, M.; Cabello-Moruno, R.; Arós, F.; Corella, D.; Ros, E.; García, M.; Estruch, R.; Martínez-González, M.A.; et al. Reduction in systemic and VLDL triacylglycerol concentration after a 3-month Mediterranean-style diet in high-cardiovascular-risk subjects. *J. Nutr. Biochem.* 2010, 21, 892–898. [CrossRef]

59. Escurriol, V.; Cofán, M.; Serra, M.; Bulló, M.; Basora, J.; Salas-Salvadó, J.; Corella, D.; Zazpe, I.; Martínez-González, M.A.; Ruiz-Gutiérrez, V.; et al. Serum sterol responses to increasing plant sterol intake from natural foods in the Mediterranean diet. *Eur. J. Nutr.* 2009, 48, 373–382. [CrossRef]

60. Fitó, M.; Guxens, M.; Corella, D.; Sáez, G.; Estruch, R.; de la Torre, R.; Francés, F.; Cabezas, C.; del Carmen López-Sabater, M.; Marrugat, J.; et al. PREDIMED Study Investigators, Effect of a traditional Mediterranean diet on lipoprotein oxidation: A randomized controlled trial. *Arch. Intern. Med.* 2007, 167, 1195–1203. [CrossRef]

61. Martínez-González, M.A.; Estruch, R.; Corella, D.; Ros, E.; Salas-Salvadó, J. Prevention of diabetes with mediterranean diets. *Ann. Intern. Med.* 2014, 161, 157–158. [CrossRef]

62. Salas-Salvadó, J.; Bulló, M.; Babio, N.; Martínez-González, M.A.; Ibarrola-Jurado, N.; Basora, J.; Estruch, R.; Covas, M.I.; Corella, D.; Arós, F.; et al. PREDIMED Study Investigators, Reduction in the incidence of type 2 diabetes with the Mediterranean diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care* 2011, 34, 14–19. [CrossRef] [PubMed]

63. Salas-Salvadó, J.; Bulló, M.; Babio, N.; Martínez-González, M.A.; Ibarrola-Jurado, N.; Basora, J.; Estruch, R.; Covas, M.I.; Corella, D.; Arós, F.; et al. PREDIMED Study Investigators, Erratum. Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care* 2018, 41, 2259–2260. [CrossRef] [PubMed]

64. Liyanage, T.; Ninomiya, T.; Wang, A.; Neal, B.; Jun, M.; Wong, M.G.; Jardine, M.; Hillis, G.S.; Perkovic, V. Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis. *PLoS ONE* 2016, 11, e0159252. [CrossRef] [PubMed]
65. Salas-Salvadó, J.; Guasch-Ferre, M.; Lee, C.H.; Estruch, R.; Clish, C.B.; Ros, E. Protective Effects of the Mediterranean Diet on Type 2 Diabetes and Metabolic Syndrome. *J. Nutr.* **2016**, *146*, 920S–927S. [CrossRef] [PubMed]

66. Esposito, K.; Maiorino, M.I.; Bellastella, G.; Chiodini, P.; Panagiotakos, D.; Giugliano, D. A journey into a Mediterranean diet and type 2 diabetes: A systematic review with meta-analyses. *BMJ Open* **2015**, *5*, e008222. [CrossRef]

67. Rumawas, M.E.; Meigs, J.B.; Dwyer, J.T.; McKeown, N.M.; Jacques, P.F. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. *Am. J. Clin. Nutr.* **2009**, *90*, 1608–1614. [CrossRef]

68. Petersson, S.D.; Philippou, E. Mediterranean Diet, Cognitive Function, and Dementia: A Systematic Review of the Evidence. *Adv. Nutr.* **2016**, *7*, 889–940. [CrossRef]

69. Van der Brandt, P.A.; Schulpen, M. Mediterranean diet adherence and risk of portmenopausal breast cancer: Results of a cohort study and meta-analysis. *Int. J. Cancer* **2017**, *140*, 2220–2231. [CrossRef]

70. Turati, F.; Cairoli, G.; Bravi, F.; Ferraroni, M.; Serraino, D.; Montella, M. Mediterranean Diet and Breast Cancer Risk. *Nutrients* **2018**, *10*, 326. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).